Abstract
Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal safety study of the first tubeless, on-body automated insulin delivery system with customizable glycemic targets. This single-arm, multicenter, prospective study enrolled 112 children (age 6-13.9 years) and 129 adults (age 14-70 years). A 2-week standard therapy phase (usual insulin regimen) was followed by 3 months of automated insulin delivery. Primary safety outcomes were incidence of severe hypoglycemia and diabetic ketoacidosis. Primary effectiveness outcomes were change in HbA1c and percent time in sensor glucose range 70-180 mg/dL ("time in range"). A total of 235 participants (98% of enrolled, including 111 children and 124 adults) completed the study. HbA1c was significantly reduced in children by 0.71% (7.8 mmol/mol) (mean ± SD: 7.67 ± 0.95% to 6.99 ± 0.63% [60 ± 10.4 mmol/mol to 53 ± 6.9 mmol/mol], P < 0.0001) and in adults by 0.38% (4.2 mmol/mol) (7.16 ± 0.86% to 6.78 ± 0.68% [55 ± 9.4 mmol/mol to 51 ± 7.4 mmol/mol], P < 0.0001). Time in range was improved from standard therapy by 15.6 ± 11.5% or 3.7 h/day in children and 9.3 ± 11.8% or 2.2 h/day in adults (bot...Continue Reading
References
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 30, 2002·Diabetes Care·Curt L RohlfingDavid E Goldstein
May 23, 2015·Diabetes Care·Kellee M MillerUNKNOWN T1D Exchange Clinic Network
Sep 16, 2016·JAMA : the Journal of the American Medical Association·Richard M BergenstalFrancine R Kaufman
May 24, 2017·The Lancet. Diabetes & Endocrinology·Alanna WeismanBruce A Perkins
Feb 13, 2018·Diabetes Technology & Therapeutics·Bruce A BuckinghamTrang T Ly
Mar 23, 2018·Diabetes Technology & Therapeutics·Tonya D RiddlesworthSteven M Willi
Aug 3, 2018·Diabetes Technology & Therapeutics·Bruce A BuckinghamTrang T Ly
Oct 8, 2018·Lancet·Martin TauschmannUNKNOWN APCam11 Consortium
Dec 27, 2018·Diabetes Technology & Therapeutics·Gregory P ForlenzaFrancine R Kaufman
Jan 19, 2019·Diabetes Technology & Therapeutics·Nicole C FosterSatish K Garg
Mar 30, 2019·Diabetes Technology & Therapeutics·Gregory P ForlenzaTrang T Ly
Jun 10, 2019·Diabetes Care·Tadej BattelinoMoshe Phillip
Aug 30, 2019·Diabetes Spectrum : a Publication of the American Diabetes Association·Cari BergetGregory P Forlenza
Sep 25, 2019·Diabetes Care·Jeremy H PettusSteven V Edelman
Oct 10, 2019·Diabetes Technology & Therapeutics·Jennifer L SherrTrang T Ly
Oct 17, 2019·The New England Journal of Medicine·Sue A BrownUNKNOWN iDCL Trial Research Group
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Aug 28, 2020·The New England Journal of Medicine·Marc D BretonUNKNOWN iDCL Trial Research Group
Dec 4, 2020·Diabetes, Obesity & Metabolism·Lalantha LeelarathnaSze M Ng
Dec 17, 2020·Diabetes Technology & Therapeutics·Gregory P ForlenzaTrang T Ly
Feb 8, 2021·Diabetologia·Charlotte K Boughton, Roman Hovorka
Mar 23, 2021·Diabetologia·Charlotte K Boughton, Roman Hovorka